Importance of potent P2Y₁₂ receptor blockade in acute myocardial infarction: focus on prasugrel

Bibliography

• Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004;2:535-45
   PubMedGoogle Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-5
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC Jr, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:1920-59
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Spencer FA, Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e89S-e119S
   PubMed Web of Science ®Google Scholar
• Cadroy Y, Bossavy JP, Thalamas C, Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823-8
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Helton TJ, Bavry AA, Kumbhani DJ, Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs 2007;7:289-97
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hayes KM, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392-6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010;56:112-16
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response [abstract]. Am J Cardiol 2006;98(8 Suppl 1):200M
   Google Scholar
• Jakubowski JA, Sugidachi A, Ogawa T, Comparative antiplatelet effects of the active metabolites of CS-747 (prasugrel, LY640315) and clopidogrel. J Thromb Haemost 2005;3(Suppl 1):P2299
   Google Scholar
• Sugidachi A, Ogawa T, Kurihara A, The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-51
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010;49:777-98
   PubMed Web of Science ®Google Scholar
• Payne CD, Li YG, Small DS, Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126-42
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006;319:1467-76
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishiya Y, Kurihara A, Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 2008;23:412-20
   PubMed Web of Science ®Google Scholar
• Schror K, Siller-Matula JM, Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol 2012;26:39-46
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Weerakkody GJ, Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007;49:167-73
   PubMed Web of Science ®Google Scholar
• Weerakkody GJ, Jakubowski JA, Brandt JT, Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-6
   PubMed Web of Science ®Google Scholar
• Jernberg T, Payne CD, Winters KJ, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
   PubMed Web of Science ®Google Scholar
• Ernest II CS, Small DS, Rohatagi S, Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn 2008;35:593-618
   PubMed Web of Science ®Google Scholar
• Li YG, Ni L, Brandt JT, Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 2009;20:316-27
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Ernest CS II, Small DS, Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-98
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, Common polymorphisms of CYP 2C19 and CYP 2C9 affect the pharmacodynamic and pharmacokinetic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36
   PubMed Web of Science ®Google Scholar
• Kirkwood S, McCorkle K, Walker J, Prasugrel and clopidogrel in Chinese CYP2C19 allelic variants following maintenance doses [abstract no. AS-248]. Am J Cardiol 2009;103(9 Suppl 1):105B
   Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:3553-60
   Web of Science ®Google Scholar
• Varenhorst C, James S, Erlinge D, Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009;30:1744-52
   PubMed Web of Science ®Google Scholar
• Small DS, Kothare P, Yuen E, The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy caucasian subjects. Eur J Clin Pharmacol 2010;66:127-35
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41
   PubMed Web of Science ®Google Scholar
• Farid N, Small D, Payne C, Effects of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacother 2008;28:1483-94
   PubMed Web of Science ®Google Scholar
• Farid NA, Jakubowski JA, Payne CD, Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin 2009;25:1821-9
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Li YG, Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008;24:2251-7
   PubMed Web of Science ®Google Scholar
• Alexopoulos D. Prasugrel resistance: fact or fiction. Platelets 2012;23:83-90
   PubMed Web of Science ®Google Scholar
• Aradi D, Kuliczkowski W, Atar D, Serebruany VL. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012;107:338-45
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Cohen R, Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010;103:213-23
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Saucedo JF, Deraad R, SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP SWitching Anti Platelet) study. J Am Coll Cardiol 2010;56:1017-23
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL III, Braunwald E, TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-63
   PubMed Web of Science ®Google Scholar
• Jeong YH, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cutoff of VASP-P platelet reactivity index too low? J Thromb Haemost 2012;10:487-9
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Dimitropoulos G, Davlouros P, Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-10
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Davlouros P, Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011;162:733-9
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Panagiotou A, Xanthopoulou I, Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379-85
   PubMed Web of Science ®Google Scholar
• Capranzano P, Tamburino C, Capodanno D, Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb Haemost 2011;106:1149-57
   PubMed Web of Science ®Google Scholar
• Bonello L, Pansieri M, Mancini J, High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73
   PubMed Web of Science ®Google Scholar
• Alexopoulos D. A prospective, randomized trial of prasugrel vs. double-dose clopidogrel in patients with ST-segment elevation myocardial infarction and clopidogrel hyporesponsiveness. Presented at Featured clinical research in TCT 2011. November 10, 2011; San Francisco, California.
   Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-63
   PubMed Web of Science ®Google Scholar
• Morrow DA, Wiviott SD, White HD, Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-64
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31
   PubMed Web of Science ®Google Scholar
• Antman EM, Wiviott SD, Murphy SA, Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-33
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Wiviott SD, Braunwald E, American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation 2012;125:577-83
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Winters KJ, Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-73
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Desai N, Murphy SA, Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011;108:905-11
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Cardiovascular and Renal Drug Advisory Committee briefing document on prasugrel for ACS. February 3, 2009. Available from: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf [Accessed 3 May 2012]
   Google Scholar
• Schafer JA, Kjesbo NK, Gleason PP. Critical review of prasugrel for formulary decision makers. J Manag Care Pharm 2009;15:335-43
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Wiviott SD, Antman EM, Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-9
   PubMed Web of Science ®Google Scholar
• Riesmeyer JS, Salazar DE, Weerakkody GJ, Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 Substudy. J Clin Pharmacol 2012;52:789-97
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Venditti F, Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012;109:214-18
   PubMed Web of Science ®Google Scholar
• Armero S, Bonello L, Berbis J, Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. Am J Cardiol 2011;108:1710-13
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr, Dehmer GJ, Kaul S, ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56:321-41
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821-30
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Vitry A, Ward MB, Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010;8:1678-84
   PubMed Web of Science ®Google Scholar
• Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clin Pharmacol Ther 2012;91:829-37
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR, Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012;379:1705-11
   PubMed Web of Science ®Google Scholar
• Montalescot G, Bolognese L, Dudek D, A comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. Am Heart J 2011;161:650-6; e1
   PubMed Web of Science ®Google Scholar
• Pride YB, Wiviott SD, Buros JL, TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J 2009;158:e21-6
   Web of Science ®Google Scholar
• O'Donoghue M, Antman EM, Braunwald E, The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009;54:678-85
   PubMed Web of Science ®Google Scholar
• Chin CT, Roe MT, Fox KA, TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22; e1
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-77
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Badimon JJ, Saucedo JF, A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838-46
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36
   PubMed Web of Science ®Google Scholar
• Berger JS, Bhatt DL, Cannon CP, The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009;54:1935-45
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Antman EM, for the TRITON-TIMI 38 Investigators. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol 2012;155:424-9
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Summary minutes of the Cardiovascular and Renal Drugs Advisory Committee February 3, 2009. Available from: http://www.fda.gov/ohrms/dockets/ac/09/minutes/2009-4412m1-Final.pdf [Accessed 3 May 2012]
   Google Scholar
• Mehta SR, Tanguay JF, Eikelboom JW, CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43
   PubMed Web of Science ®Google Scholar
• Mak KH, Bhatt DL, Shao M, Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009;157:658-65
   PubMed Web of Science ®Google Scholar
• Small DS, Payne CD, Kothare P, Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and White volunteers: an open-label trial. Clin Ther 2010;32:365-79
   PubMed Web of Science ®Google Scholar
• Yokoi H, Kimura T, Isshiki T, Pharmacodynamic assessment of a novel P2Y(12) receptor antagonist in Japanese patients with coronary arterydisease undergoing elective percutaneous coronary intervention. Thromb Res 2012;129:623-8
   PubMed Web of Science ®Google Scholar
• Ge J, Zhu J, Hong BK, Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Curr Med Res Opin 2010;26:2077-85
   PubMed Web of Science ®Google Scholar
• Leadbeater PD, Kirkby NS, Thomas S, Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost 2011;9:2050-6
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla DM, Carroll K, PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011;124:544-54
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Arnold SV, Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-9
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012;59:2159-64
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, GIFT Investigators. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) Study. J Am Coll Cardiol 2012;59:1928-37
   PubMed Web of Science ®Google Scholar
• Jeong YH, Kim IS, Park Y, Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010;3:731-41
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84
   PubMed Web of Science ®Google Scholar